Literature DB >> 8547241

HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.

R A Spence1, K S Anderson, K A Johnson.   

Abstract

The parameters governing the polymerization mechanism of reverse transcriptase containing the tyrosine to cysteine mutation at position 181 (Y181C) were determined using pre-steady-state techniques. The pathway for single nucleotide incorporation catalyzed by Y181C is similar to that determined for wild-type RT where a rate-limiting conformational change precedes fast chemistry and is followed by slow steady-state release of the primer/template. The Y181C mutant enzyme binds a 25/45-mer duplex DNA tightly with a Kd of 11 nM. However, the Y181C mutation weakens the nucleotide affinity 2-3-fold relative to the wild-type complex. We also determined the parameters governing the mechanism of nonnucleoside inhibitor resistance with Y181C. The Kd value of Nevirapine with the mutant E.DNA complex increased approximately 500-fold. The decreased affinity of Nevirapine for the mutant enzyme is a consequence of a faster inhibitor dissociation rate from the enzyme complex of Y181C relative to that of the wild-type. The E.DNA complex of Y181C may be saturated with Nevirapine, and the I.E.DNA complex is capable of a maximum incorporation rate of 0.1 s-1 (a 10-fold faster rate than that of the wild-type I.E.DNA complex). The overall two-step binding of nucleotide to Y181C in the presence of Nevirapine remains unaffected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8547241     DOI: 10.1021/bi952058+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.

Authors:  Matthew M Schuckmann; Bruno Marchand; Atsuko Hachiya; Eiichi N Kodama; Karen A Kirby; Kamalendra Singh; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2010-09-27       Impact factor: 5.157

2.  Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.

Authors:  Qing Xia; Jessica Radzio; Karen S Anderson; Nicolas Sluis-Cremer
Journal:  Protein Sci       Date:  2007-08       Impact factor: 6.725

3.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

6.  The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Authors:  P Gerondelis; R H Archer; C Palaniappan; R C Reichman; P J Fay; R A Bambara; L M Demeter
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.

Authors:  John P Barnard; Kelly D Huber; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

8.  Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Eugene L Asahchop; Matthew McCallum; Peter K Quashie; Yingshan Han; Yudong Quan; Mark A Wainberg
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

9.  Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.

Authors:  R H Archer; C Dykes; P Gerondelis; A Lloyd; P Fay; R C Reichman; R A Bambara; L M Demeter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

10.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.